Brochure
11 Nov 2023

Alteogen signs global licence deal with Sandoz

Sandoz will have global rights to use Alteogen’s ALT-B4 to develop and commercialise a subcutaneous version of a biosimilar product.

Content provided by our supplier

Alteogen

  • KR
  • 2023
    On CPHI since

Other Content from Alteogen ()